Last reviewed · How we verify
Hyperbaric Prilocaine 1%
Hyperbaric Prilocaine 1% is a Local anesthetic Small molecule drug developed by Dr. Pere Roura-Poch. It is currently FDA-approved for Local and regional anesthesia for surgical and diagnostic procedures, Spinal anesthesia.
Prilocaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.
Prilocaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. Used for Local and regional anesthesia for surgical and diagnostic procedures, Spinal anesthesia.
At a glance
| Generic name | Hyperbaric Prilocaine 1% |
|---|---|
| Sponsor | Dr. Pere Roura-Poch |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Prilocaine works by inhibiting sodium influx through voltage-gated sodium channels in nerve fibers, which prevents depolarization and transmission of pain signals. The 'hyperbaric' formulation indicates the solution has a specific gravity greater than cerebrospinal fluid, affecting its distribution when used for spinal anesthesia. This allows for localized anesthesia in a specific anatomical region.
Approved indications
- Local and regional anesthesia for surgical and diagnostic procedures
- Spinal anesthesia
Common side effects
- Transient neurological symptoms (TNS)
- Hypotension
- Bradycardia
- Headache
- Methemoglobinemia (rare, dose-dependent)
Key clinical trials
- Intrathecal Prilocaine and Adductor Canal Block vs Intrathecal Bupivacaine Alone for Ambulatory Knee Arthroscopy (PHASE4)
- Effect of Subarachnoid Block and Femoropopliteal Block to Limb Perfusion in PAD Patients (NA)
- Efficacy and Safety of Prilocaine 2% and Lidocaine 5% Hyperbaric Against Spinal Anesthesia in Post Cystoscopy Procedure (PHASE4)
- Cardiovascular Effects of Intrathecal Hyperbaric Prilocaine or Bupivacaine in Surgery Under Spinal Anesthesia (NA)
- Spinal Prilocaine for Caesarian Sections (NA)
- Hyperbaric Bupivacaine Versus Hyperbaric Prilocaine 2% for Cesarean Section Under Spinal Anesthesia (PHASE3)
- Estimation of the ED95 of Intrathecal Hyperbaric Prilocaine 2% With Sufentanyl for Scheduled Cesarean Delivery (PHASE2)
- Estimation of the Effective Dose (ED) 95 of Intrathecal Hyperbaric Prilocaine 2% for Scheduled Cesarean Delivery. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hyperbaric Prilocaine 1% CI brief — competitive landscape report
- Hyperbaric Prilocaine 1% updates RSS · CI watch RSS
- Dr. Pere Roura-Poch portfolio CI
Frequently asked questions about Hyperbaric Prilocaine 1%
What is Hyperbaric Prilocaine 1%?
How does Hyperbaric Prilocaine 1% work?
What is Hyperbaric Prilocaine 1% used for?
Who makes Hyperbaric Prilocaine 1%?
What drug class is Hyperbaric Prilocaine 1% in?
What development phase is Hyperbaric Prilocaine 1% in?
What are the side effects of Hyperbaric Prilocaine 1%?
What does Hyperbaric Prilocaine 1% target?
Related
- Drug class: All Local anesthetic drugs
- Target: All drugs targeting Voltage-gated sodium channels
- Manufacturer: Dr. Pere Roura-Poch — full pipeline
- Therapeutic area: All drugs in Anesthesia
- Indication: Drugs for Local and regional anesthesia for surgical and diagnostic procedures
- Indication: Drugs for Spinal anesthesia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing